摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(10S)-2-hydroxy-3-[(1R)-1-hydroxyheptyl]-10-[(S)-hydroxy-[(2S)-6-oxo-2,3-dihydropyran-2-yl]methyl]-6,14-dioxatricyclo[10.3.0.04,8]pentadeca-1(12),4(8)-diene-5,7,13,15-tetrone | 21794-01-4

中文名称
——
中文别名
——
英文名称
(10S)-2-hydroxy-3-[(1R)-1-hydroxyheptyl]-10-[(S)-hydroxy-[(2S)-6-oxo-2,3-dihydropyran-2-yl]methyl]-6,14-dioxatricyclo[10.3.0.04,8]pentadeca-1(12),4(8)-diene-5,7,13,15-tetrone
英文别名
——
(10S)-2-hydroxy-3-[(1R)-1-hydroxyheptyl]-10-[(S)-hydroxy-[(2S)-6-oxo-2,3-dihydropyran-2-yl]methyl]-6,14-dioxatricyclo[10.3.0.04,8]pentadeca-1(12),4(8)-diene-5,7,13,15-tetrone化学式
CAS
21794-01-4
化学式
C26H30O11
mdl
——
分子量
518.5
InChiKey
ZJTBTDVZNGBSNG-WTFOXLIOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    176°C
  • 沸点:
    522.6°C (rough estimate)
  • 密度:
    1.2767 (rough estimate)
  • 颜色/状态:
    CRYSTALIZES FROM DIETHYL ETHER AS ROSETTES OF NEEDLES; FROM BENZENE & ETHYL ACETATE AS LONG LATHES; HEXAGONAL PLATES FROM AMYL ACETATE
  • 溶解度:
    PARTIALLY SOL IN WATER, FAIRLY SOL IN ALC & ESTERS & VERY SOL IN ACETONE /RUBRATOXINS/
  • 稳定性/保质期:
    STABLE AT ROOM TEMP /RUBRATOXINS/
  • 旋光度:
    Specific optical rotation: +67 deg (acetone, 20 °C, c=2)
  • 分解:
    When heated to decomposition it emits acrid smoke and irritating fumes.
  • 解离常数:
    PKA= 4.69

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    37
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    174
  • 氢给体数:
    3
  • 氢受体数:
    11

ADMET

代谢
三羧酸循环不仅用于将葡萄糖完全氧化成二氧化碳和水,还为一些次级代谢物的生物合成提供中间体,包括类胡萝卜素毒素...第一步涉及癸酸与草酰乙酸的缩合,这一过程类似于柠檬酸的形成。随后的脱水、脱羧和氧化导致形成一个中间酐,该酐二聚化并在进一步氧化后形成类胡萝卜素毒素A。氧气功能在哪个阶段引入尚不清楚,特别是,这样一个假设将意味着α,β-不饱和γ-内酯的羧基来自乙酸盐的甲基碳。/类胡萝卜素毒素/
AS WELL AS SERVING TO COMPLETE THE OXIDATION OF GLUCOSE TO CO2 & WATER, THE TRICARBOXYLIC ACID CYCLE ALSO PROVIDES INTERMEDIATES FOR THE BIOSYNTHESIS OF SOME SECONDARY METABOLITES, INCL THE RUBRATOXINS... THE FIRST STEP INVOLVES CONDENSATION OF DECANOIC ACID WITH OXALOACETIC ACID IN A MANNER ANALOGOUS TO THE FORMATION OF CITRIC ACID. SUBSEQUENT DEHYDRATION, DECARBOXYLATION & OXIDATION LEAD TO AN INTERMEDIATE ANHYDRIDE WHICH DIMERIZES TO FORM, AFTER FURTHER OXIDATION, RUBRATOXIN A. AT WHAT STAGE THE OXYGEN FUNCTIONS ARE INTRODUCED IS NOT CLEAR, &, IN PARTICULAR, SUCH A HYPOTHESIS WOULD MEAN THAT THE CARBOXYL GROUP OF THE ALPHA,BETA-UNSATURATED GAMMA-LACTONE WOULD BE DERIVED FROM THE METHYL CARBON OF ACETATE. /RUBRATOXINS/
来源:Hazardous Substances Data Bank (HSDB)
代谢
肝脏代谢Ruby毒素。存在多种代谢物。在大鼠中,葡萄糖苷酸和硫酸盐结合物被排入胆汁,在肠道中显然被水解,母体毒素可能通过肠肝循环再次被吸收。还形成了未知的代谢物。/Ruby毒素/
THE LIVER METABOLIZES RUBRATOXINS. THERE ARE A NUMBER OF METABOLITES. IN RATS, GLUCURONIDE & SULFATE CONJUGATES ARE EXCRETED IN BILE, APPARENTLY HYDROLYZED IN THE INTESTINE, & THE PARENT TOXIN MAY BE RESORBED IN AN ENTEROHEPATIC CYCLE. UNKNOWN METABOLITES ARE ALSO FORMED. /RUBRATOXINS/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
在接受了红毒素B(25毫克/千克,每周三次,持续5周)处理并在此期间喂食含有0.1 ppm的黄曲霉毒素B1饮食的大鼠中,发现了红毒素B致死作用增强的证据,但并未发现黄曲霉毒素B1致癌作用的增强。
EVIDENCE OF POTENTIATION OF THE LETHAL ACTION OF RUBRATOXIN B, BUT NOT THE CARCINOGENIC ACTION OF AFLATOXIN B1, WAS FOUND IN RATS TREATED WITH RUBRATOXIN B (25 MG/KG, 3 TIMES/WK FOR 5 WK) & FED OVER THE SAME PERIOD A DIET CONTAINING 0.1 PPM AFLATOXIN B1.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
在同时给药实验中,使用 Sprague-Dawley 大鼠,当存在 5 毫克/公斤的Rubratoxin B时,Ochratoxin A的新生儿LD50值比单独Ochratoxin A的LD50值降低了16倍。在Ochratoxin存在的情况下,Rubratoxin B的新生儿LD50降低了4倍。在实验中,当第一天给予Rubratoxin B,第十五天给予Aflatoxin B1时,体重增加的减少是由两种试剂共同作用而不是单独作用引起的。然而,当第一天给予Aflatoxin B1,或者在先用Ochratoxin后用Rubratoxin的实验中,并没有显示出协同反应。
IN SIMULTANEOUS DOSING EXPT /WITH SPRAGUE-DAWLEY RATS/, THE NEONATE LD50 VALUE OF OCHRATOXIN A IN THE PRESENCE OF 5 MG/KG RUBRATOXIN B WAS REDUCED 16-FOLD BELOW THE LD50 VALUE OF OCHRATOXIN A ALONE. THE NEONATE LD50 OF RUBRATOXIN B WAS DECR 4-FOLD IN THE PRESENCE OF OCHRATOXIN. IN EXPT WHEN RUBRATOXIN B WAS ADMIN ON DAY ONE & AFLATOXIN B1 ON DAY 15, DECR WT GAINS WERE MEDIATED BY BOTH AGENTS RATHER THAN BY EITHER AGENT ALONE. A SYNERGISTIC RESPONSE, HOWEVER, WAS NOT DEMONSTRATED WHEN AFLATOXIN B1 WAS GIVEN ON DAY 1 OR IN EXPT USING OCHRATOXIN FOLLOWED BY RUBRATOXIN.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
使用丙二醇作为溶剂,雄性小鼠的急性腹腔LD50估计为1.42毫克/千克。戊巴比妥预处理可降低毒性约42%,而阉割或预先使用SKF-525A分别增加毒性20%和60%。红霉素B增强了戊巴比妥诱导的CNS抑制和增强戊巴比妥低体温。在另一项实验中,戊巴比妥预处理降低了毒性约20%,而SKF-525A预处理增加了毒性近50%。二乙基马来酸盐预处理也显示出增加的毒性,这表明谷胱甘肽具有保护作用。这些数据表明,增加混合功能氧化酶活性与降低红霉素B毒性有关,进一步暗示红霉素B而非代谢物是活性形式。
USING PROPYLENE GLYCOL AS THE SOLVENT, THE ACUTE IP LD50 IN MALE MICE WAS EST AT 1.42 MG/KG. PRETREATMENT WITH SC PELLETS OF PENTOBARBITAL REDUCED TOXICITY APPROX 42% WHILE CASTRATION OR PRETREATMENT WITH SKF-525A INCR TOXICITY 20% & 60%, RESPECTIVELY. RUBRATOXIN B POTENTIATED PENTOBARBITAL-INDUCED /SRP: CNS DEPRESSION/ & ENHANCED PENTOBARBITAL HYPOTHERMIA. /IN ANOTHER EXPT/...PRETREATMENT WITH PENTOBARBITAL REDUCED TOXICITY APPROX 20% WHILE SKF-525A PRETREATMENT INCR TOXICITY NEARLY 50%. DIETHYL MALEATE PRETREATMENT ALSO DEMONSTRATED ENHANCED TOXICITY, SUGGESTING A PROTECTIVE ACTION OF GLUTATHIONE. THESE DATA SUGGEST THAT INCR MIXED FUNCTION OXIDASE ACTIVITY IS ASSOC WITH DECR RUBRATOXIN B TOXICITY, FURTHER IMPLYING THAT RUBRATOXIN B & NOT A METABOLITE IS THE ACTIVE FORM.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
单独使用RUBRATOXIN以及与AFALOTOXIN联合口服给予豚鼠...3周后产生的死亡率高于单独使用RUBRATOXIN所产生的。
THE EFFECTS OF RUBRATOXIN ALONE IN COMBINATION WITH AFLATOXIN GIVEN ORALLY TO GUINEA PIGS...FOR 3 WK PRODUCED MORTALITY HIGHER THAN PRODUCED BY RUBRATOXIN ALONE.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
/SRP:/ 基本治疗:建立专利气道。如有必要,进行吸痰。观察呼吸不足的迹象,如有需要,协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿,如有必要,进行治疗……监测休克,如有必要,进行治疗……预计可能出现癫痫,如有必要,进行治疗……对于眼睛污染,立即用水冲洗眼睛。在运输过程中,用生理盐水连续冲洗每只眼睛……不要使用催吐剂。对于摄入,如果患者能吞咽、有强烈的干呕反射且不流口水,则用水冲洗口腔,并给予5毫升/千克,最多200毫升的水进行稀释……在去污染后,用干燥的无菌敷料覆盖皮肤烧伤……/毒药A和B/
/SRP:/ Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
放射性标记的RUBRATOXIN B(14)C在小鼠和大鼠中的排泄模式...在最初的24小时内排泄了40-50%的施用放射性。主要的排泄途径是通过呼吸的CO2,在小鼠中占施用(14)C的30%,在大鼠中占35%。6到9%通过尿液排出;粪便中的放射性活性较少。来自RUBRATOXIN的放射性活性在给药后一小时内以最高水平出现在肝脏和肾脏中;其他器官中发现了较少的量。放射性活性的浓度在肝组织中最高。
EXCRETION PATTERNS OF (14)C DERIVED FROM RADIOLABELED RUBRATOXIN B...IN MICE & RATS...EXCRETED 40-50% OF THE ADMIN RADIOACTIVITY DURING THE INITIAL 24 HR. A MAJOR EXCRETORY ROUTE WAS RESP CO2 WHICH ACCOUNTED FOR 30% OF THE ADMIN (14)C IN MICE & 35% IN RATS. 6 TO 9% WAS EXCRETED IN THE URINE; LESS RADIOACTIVITY WAS PRESENT IN FECES. RADIOACTIVITY DERIVED FROM RUBRATOXIN WAS PRESENT AT MAX LEVELS IN LIVER & KIDNEYS ONE HR AFTER ADMIN; SMALLER AMT WERE FOUND IN OTHER ORGANS. THE CONCN OF RADIOACTIVITY WAS GREATEST IN LIVER TISSUE.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
放射性标记的rubratoxin B(14)C在小鼠和大鼠中的排泄模式...在注射后1/2小时内,所有可检测到的放射性都存在于微粒体上清液中。在前2小时内,线粒体中的放射性物质逐渐增加,而微粒体上清液中的放射性物质相应减少。在24小时时,线粒体部分含有大约14%的肝脏放射性,而80%的放射性仍留在溶液部分。在24小时期间,微粒体部分含有4%到10%的肝脏放射性。
EXCRETION PATTERNS OF (14)C DERIVED FROM RADIOLABELED RUBRATOXIN B...IN MICE & RATS. ...ALL DETECTABLE RADIOACTIVITY PRESENT IN THE LIVER 1/2 HR AFTER INJECTION WAS IN THE MICROSOMAL SUPERNATANT FLUID. WITHIN THE FIRST 2 HR, INCR AMT OF RADIOACTIVITY WERE FOUND IN THE MITOCHONDRIA WITH A CONCOMITANT DECR IN THE MICROSOMAL SUPERNATANT FLUID. AT 24 HR, THE MITOCHONDRIAL FRACTION CONTAINED APPROX 14% OF THE LIVER RADIOACTIVITY WITH 80% REMAINING IN THE SOL FRACTION. THE MICROSOMAL FRACTION CONTAINED 4 TO 10% OF THE LIVER RADIOACTIVITY DURING THE 24-HR PERIOD.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
排泄物、肾脏和肝脏组织浓度以及从血浆浓度估算的药代动力学参数对给予单次IP剂量的(14)C-红霉素B的大鼠进行了测定(0.05毫克溶于丙二醇中)。到第7天,80%的管理放射性已排泄到尿液中(41.7%)和粪便中(38.7%)。尿液排泄主要是原形化合物,占7天内排泄的放射活性的75%。肾脏中放射性物质的消除是单相的,半衰期为97.35小时。肝脏中放射性物质的消除是双相的,慢相的半衰期为13.66小时。红霉素B及其衍生的放射性(来自原化合物和代谢产物的放射性)从血浆中的消除是双相的。消除的快速相的半衰期为2.57和1.08小时,慢相的半衰期为60.80和100.46小时,分别对应红霉素B和(14)C-红霉素B衍生的放射性。长的血浆半衰期提示存在肠肝循环。放射性物质浓度在肝脏中最高为1小时,在血浆中为2小时。除注射后最初几小时外,肝脏中的放射性物质浓度从未显著超过血浆中的浓度,这表明存在被动吸收过程。
EXCRETION, TISSUE CONCN IN KIDNEY & LIVER, & PHARMACOKINETIC PARAMETERS ESTIMATED FROM PLASMA BLOOD CONCN WERE DETERMINED FOR RATS GIVEN A SINGLE IP DOSE OF (14)C-RUBRATOXIN B (0.05 MG DISSOLVED IN PROPYLENE GLYCOL). BY 7 DAYS, 80% OF ADMIN RADIOACTIVITY WAS EXCRETED INTO THE URINE (41.7%) & FECES (38.7%). URINARY EXCRETION WAS PRIMARILY AS THE PARENT COMPOUND, ACCOUNTING FOR 75% OF RADIOACTIVITY EXCRETED BY 7 DAYS. ELIMINATION OF RADIOACTIVITY FROM KIDNEYS WAS MONOPHASIC WITH T/2 OF 97.35 HR. ELIMINATION OF RADIOACTIVITY FROM LIVER WAS BIPHASIC, WITH T/2 OF 13.66 HR FOR THE SLOW PHASE. ELIMINATION OF RUBRATOXIN B & (14)C-RUBRATOXIN B-DERIVED RADIOACTIVITY (RADIOACTIVITY DERIVED FROM BOTH THE PARENT COMPOUND & METABOLITES) FROM PLASMA WAS BIPHASIC. THE RAPID PHASES OF ELIMINATION HAD T/2 OF 2.57 & 1.08 HR, & SLOW PHASES HAD T/2 OF 60.80 & 100.46 HR FOR RUBRATOXIN B & (14)C-RUBRATOXIN B-DERIVED RADIOACTIVITY RESPECTIVELY. THE LONG PLASMA T/2 IS SUGGESTIVE OF ENTEROHEPATIC CIRCULATION. THE CONCN OF RADIOACTIVITY WAS GREATEST AT 1 HR IN LIVER & 2 HR IN PLASMA. EXCEPT FOR THE FIRST FEW HR FOLLOWING INJECTION, THE CONCN OF RADIOACTIVITY IN LIVER NEVER EXCEEDED SIGNIFICANTLY THAT IN THE PLASMA, SUGGESTING A PASSIVE ABSORPTION PROCESS.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xn
  • 危险类别码:
    R22
  • RTECS号:
    GX9275000
  • 包装等级:
    III
  • 危险类别:
    6.1(b)

SDS

SDS:c7322b8136c574e9fe1a1888da0c855b
查看

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物